Restricted accessResearch articleFirst published online 2023-10
Can brexpiprazole be switched safely in patients with schizophrenia and dopamine supersensitivity psychosis? A retrospective analysis in a real-world clinical practice
Several studies have reported that a switch to the dopamine partial agonist (DPA) aripiprazole (ARP), especially when the switch is abrupt, is likely to fail and sometimes worsen psychosis in schizophrenia patients already under high-dose antipsychotic treatment. Such a switching failure is speculated to be related to be the dopamine supersensitivity state. The risks of switching to the DPA brexpiprazole (BREX) have not been reported.
Aims and Methods:
We retrospectively analyzed the cases of 106 patients with schizophrenia to identify any factors related to the success or failure of switching to BREX.
Results:
The comparison between the patients with dopamine supersensitivity psychosis (n = 44) and those without (n = 62) revealed no significant difference in the switching failure judged at the sixth week. A comparison of the patients with successful switching (n = 80) and those who failed (n = 26) revealed that patients with treatment-resistant schizophrenia (TRS) were significantly more likely to fail. A logistic regression analysis also revealed that patients with past failure of switching to ARP are likely to succeed in switching to BREX. The 2-year follow-up of the patients with successful switching to BREX suggested that the patients who were treated with BREX, even temporarily, experienced some improvement in their Global Assessment of Functioning and Clinical Global Impression-Severity scores.
Conclusions:
Overall, the results indicate that patients with schizophrenia can be switched more safely to BREX compared to ARP. However, the failure of switching to BREX could be higher in patients with TRS, and thus, starting BREX treatment in refractory patients warrants careful monitoring.
AmadaNAkazawaHOhgiY, et al. (2019) Brexpiprazole has a low risk of dopamine D2 receptor sensitization and inhibits rebound phenomena related to D2 and serotonin 5-HT2A receptors in rats. Neuropsychopharmacol Rep39: 279–288.
2.
AmatoDCannevaFCummingP, et al. (2020) A dopaminergic mechanism of antipsychotic drug efficacy, failure, and failure reversal: the role of the dopamine transporter. Mol Psychiatry25: 2101–2118.
3.
AmatoDVernonACPapaleoF (2018) Dopamine, the antipsychotic molecule: A perspective on mechanisms underlying antipsychotic response variability. Neurosci Biobehav Rev85: 146–159.
4.
BowtellMEatonSThienK, et al. (2018). Rates and predictors of relapse following discontinuation of antipsychotic medication after a first episode of psychosis. Schizophr Res195: 231–236.
5.
CaseyDECarsonWHSahaAR, et al. (2003) Switching patients to aripiprazole from other antipsychotic agents: A multicenter randomized study. Psychopharmacology (Berl)166: 391–399.
6.
ChouinardG (1991) Severe cases of neuroleptic-induced supersensitivity psychosis. Diagnostic criteria for the disorder and its treatment. Schizophr Res5: 21–33.
7.
ChouinardGChouinardVA (2008) Atypical antipsychotics. CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes. Psychother Psychosom77: 69–77.
8.
ChouinardGJonesBD (1978) Neuroleptic-induced supersensitivity psychosis. Am J Psychiatry135: 1409–1410.
9.
ChouinardGSamahaANChouinardVA, et al. (2017) Antipsychotic-induced dopamine supersensitivity psychosis: Pharmacology, criteria, and therapy. Psychother Psychosom86: 189–219.
10.
CorrellCUShiLWeissC, et al. (2019) Successful switching of patients with acute schizophrenia from another antipsychotic to brexpiprazole: Comparison of clinicians’ choice of cross-titration schedules in a post hoc analysis of a randomized, double-blind, maintenance treatment study. CNS Spectr24: 507–517.
11.
CorrellCUSkubanAOuyangJ, et al. (2015) Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: A 6-week randomized, double-blind, placebo-controlled trial. Am J Psychiatry172: 870–880.
12.
FleischhackerWWHobartMOuyangJ, et al. (2017) Efficacy and safety of brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia: A randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol20: 11–21.
13.
ForbesAHobartMOuyangJ, et al. (2018) A long-term, open-label study to evaluate the safety and tolerability of brexpiprazole as maintenance treatment in adults with schizophrenia. Int J Neuropsychopharmacol21: 433–441.
14.
FrankelJSSchwartzTL (2017) Brexpiprazole and cariprazine: Distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole. Ther Adv Psychopharmacol7: 29–41.
15.
GirgisRRForbesAAbi-DarghamA, et al. (2020) A positron emission tomography occupancy study of brexpiprazole at dopamine D2 and D3 and serotonin 5-HT1A and 5-HT2A receptors, and serotonin reuptake transporters in subjects with schizophrenia. Neuropsychopharmacology45: 786–792.
16.
GründerGFellowsCJanouschekH, et al. (2008) Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: An [18F]fallypride PET study. Am J Psychiatry165: 988–995.
17.
HaddadPMBrainCScottJ, et al. (2014) Nonadherence with antipsychotic medication in schizophrenia: Challenges and management strategies. Patient Relat Outcome Meas5: 43–62.
18.
HäfnerHan der HeidenW (1997) Epidemiology of schizophrenia. Can J Psychiatry42: 139–151.
19.
HartXMSchmitzCNGründerG (2022) Molecular imaging of dopamine partial agonists in humans: Implications for clinical practice. Front Psychiatry13: 832209.
20.
IshigookaJIwashitaSTadoriY (2018) Long-term safety and effectiveness of brexpiprazole in Japanese patients with schizophrenia: A 52-week, open-label study. Psychiatr Clin Neurosci72: 445–453.
21.
IshigookaJUsamiTIwashitaS, et al. (2020) Post-hoc analysis investigating the safety and efficacy of brexpiprazole in Japanese patients with schizophrenia who were switched from other antipsychotics in a long-term study (secondary publication). Neuropsychopharmacol Rep40: 122–129.
22.
IyoMTadokoroSKanaharaN, et al. (2013) Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis. J Clin Psychopharmacol33: 398–404.
23.
KanaharaNKimuraHOdaY, et al. (2021) Recent discussions on dopamine supersensitivity psychosis: Eight points to consider when diagnosing treatment-resistant schizophrenia. Curr Neuropharmacol19: 2214–2226.
24.
KanaharaNTakaseMSasakiT, et al. (2020) The effectiveness of very slow switching to aripiprazole in schizophrenia patients with dopamine supersensitivity psychosis: A case series from an open study. Int Clin Psychopharmacol35: 338–344.
25.
KaneJMAgidOBaldwinML, et al. (2019) Clinical guidance on the identification and management of treatment-resistant schizophrenia. J Clin Psychiatry80: 18com12123.
26.
KaneJMSkubanAOuyangJ, et al. (2015) A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophr Res164: 127–135.
27.
KegelesLSSlifsteinMFrankleWG, et al. (2008) Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride. Neuropsychopharmacology33: 3111–3125.
28.
KimuraHKanaharaNIyoM (2021) Rationale and neurobiological effects of treatment with antipsychotics in patients with chronic schizophrenia considering dopamine supersensitivity. Behav Brain Res403: 113126.
29.
KimuraHKanaharaNKomatsuN, et al. (2014) A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis. Schizophr Res155: 52–58.
30.
KimuraHKanaharaNSasakiT, et al. (2016) Risperidone long-acting injectable in the treatment of treatment-resistant schizophrenia with dopamine supersensitivity psychosis: Results of a 2-year prospective study, including an additional 1-year follow-up. J Psychopharmacology30: 795–802.
31.
KirkpatrickBAlphsLBuchananRW (1992) The concept of supersensitivity psychosis. J Nerv Ment Dis180: 265–270.
LinHCChongMYLeeY, et al. (2009) Switching of antipsychotics to aripiprazole in the treatment of schizophrenia. Chang Gung Med J32: 409–416.
34.
MaedaKSuginoHAkazawaH, et al. (2014) Brexpiprazole I: In vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther350: 589–604.
35.
MamoDGraffAMizrahiR, et al. (2007) Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: A triple tracer PET study. Am J Psychiatry164: 1411–1417.
36.
MoncrieffJ (2006) Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr Scand114: 3–13.
37.
ObayashiYMitsuiSSakamotoS, et al. (2020) Switching strategies for antipsychotic monotherapy in schizophrenia: A multi-center cohort study of aripiprazole. Psychopharmacology (Berl)237: 167–175.
Otsuka Pharmaceutical Co., Ltd. (2018) Population-based pharmacokinetic analyses of brexpiprazole in Japanese healthy subjects and patients with schizophrenia. In Japanese. Otsuka Pharmaceutical Co., Ltd.
40.
PaeCUSerrettiAChiesaA, et al. (2009) Immediate versus gradual suspension of previous treatments during switch to aripiprazole: Results of a randomized, open label study. Eur Neuropsychopharmacology19: 562–570.
41.
PotkinSGKaneJMCorrellCU, et al. (2020) The neurobiology of treatment-resistant schizophrenia: Paths to antipsychotic resistance and a roadmap for future research. NPJ Schizophr6: 1.
42.
StahlSM (2016) Mechanism of action of brexpiprazole: Comparison with aripiprazole. CNS Spectr21: 1–6.
43.
SuzukiTKanaharaNYamanakaH, et al. (2015) Dopamine supersensitivity psychosis as a pivotal factor in treatment-resistant schizophrenia. Psychiatr Res227: 278–282.
44.
TadokoroSOkamuraNSekineY, et al. (2012) Chronic treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis. Schizophr Bull38: 1012–1020.
45.
TakaesuYKishimotoTMurakoshiA, et al. (2016) Factors associated with discontinuation of aripiprazole treatment after switching from other antipsychotics in patients with chronic schizophrenia: A prospective observational study. Psychiatr Res236: 71–74.
46.
TakaseMKanaharaNOdaY, et al. (2015) Dopamine supersensitivity psychosis and dopamine partial agonist: A retrospective survey of failure of switching to aripiprazole in schizophrenia. J Psychopharmacol29: 383–389.
47.
TakeuchiHRemingtonGA (2013) Systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder. Psychopharmacology (Berl)228: 175–185.
48.
TakeuchiHRemingtonG (2018) Can aripiprazole worsen psychosis in schizophrenia? A meta-analysis of double-blind, randomized, controlled trials. J Clin Psychiatry79: 17r11489.
49.
TakeuchiHUchidaHSuzukiT, et al. (2009) Predictors of clinical worsening after a switch to aripiprazole in patients with schizophrenia: A 1-year naturalistic follow-up study. J Clin Psychopharmacol29: 394–395.
50.
TaylorMChaudhryICrossM, et al. (2005) Towards consensus in the long-term management of relapse prevention in schizophrenia. Hum Psychopharmacol20: 175–181.
51.
TibrewalPNairPCGregoryKJ, et al. (2023) Does clozapine treat antipsychotic-induced behavioural supersensitivity through glutamate modulation within the striatum?Mol Psychiatry. Epub ahead of print 17 March 2023. DOI: 10.1038/s41380-023-02026-x.
52.
WongDFRaoufiniaABricmontP, et al. (2021) An open-label, positron emission tomography study of the striatal D2/D3 receptor occupancy and pharmacokinetics of single-dose oral brexpiprazole in healthy participants. Eur J Clin Pharmacol77: 717–725.
53.
YokoiFGründerGBiziereK, et al. (2002) Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): A study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology27: 248–259.
54.
YoshimuraYShimizuHYamashitaR, et al. (2020) Association between previous high-dose antipsychotic therapy and brexpiprazole discontinuation after the initiation of brexpiprazole in patients with schizophrenia or schizoaffective disorder. Int Clin Psychopharmacol35: 98–104.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
